U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

WORK GROUP ON LINDE CERAMICS PLANT

+ + + + +

MONDAY FEBRUARY 14, 2011

+ + + + +

The Work Group convened via teleconference at 11:00 a.m., Genevieve Roessler, Chair, presiding.

PRESENT:

GENEVIEVE S. ROESSLER, Chair JOSIE BEACH, Member R. WILLIAM FIELD, Member MICHAEL H. GIBSON, Member JAMES E. LOCKEY, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official ISAF AL-NABULSI, DOE ROBERT ANIGSTEIN, SC&A ANTOINETTE BONSIGNORE CHRIS CRAWFORD, DCAS JASON DAVIS, ORAU Team MONICA HARRISON-MAPLES, ORAU Team EMILY HOWELL, HHS JEFFREY KOTSCH, DOL JENNY LIN, HHS LINDA LUX JOHN MAURO, SC&A JIM NETON, DCAS STEVE OSTROW, SC&A LAVON RUTHERFORD, DCAS MUTTY SHARFI, ORAU Team

C-O-N-T-E-N-T-S

Page I.	Welcome and roll call/	4
	introductions	•
II.	Summary of December 7 Linde WG Teleconference and pertinent portion of January 12 ABRWH meeting	9
III.	Discussion of "Revised SEC Petition Evaluation Report"	10
IV.	Presentation of any modifications to dose reconstruction by NIOSH and discussion by SC&A and WG	13
V.	Discussion of ABRWH Chair Melius's concerns about lack of information on activities at the site	25
VI.	Plans for presentation at February 24 ABRWH meeting	44

1	P-R-O-C-E-E-D-I-N-G-S
2	11:02 a.m.
3	MR. KATZ: This is the Advisory
4	Board on Radiation and Worker Health, Linde
5	Work Group.
6	Let's begin with roll call with
7	Board Members, beginning with the Chair.
8	CHAIR ROESSLER: This is Gen
9	Roessler, Chair of the Work Group, no conflict
10	with Linde.
11	MR. KATZ: Thank you.
12	MEMBER LOCKEY: Jim Lockey, no
13	conflict.
14	MEMBER BEACH: Josie Beach, no
15	conflict.
16	MEMBER GIBSON: Mike Gibson, no
17	conflict.
18	MR. KATZ: Okay. And any other
19	Board Members?
20	MEMBER FIELD: Have you got me?
21	MR. KATZ: And Bill Field.
22	CHAIR ROESSLER: Did you say Dr.

- 1 Field came on?
- 2 MEMBER FIELD: Yes.
- 3 MR. KATZ: Dr. Field is on, Bill
- 4 is on.
- 5 CHAIR ROESSLER: Good.
- 6 MR. KATZ: Let's go to NIOSH ORAU
- 7 team.
- 8 MR. CRAWFORD: This is Chris
- 9 Crawford, no conflict.
- 10 DR. NETON: Jim Neton, no
- 11 conflict, NIOSH.
- MR. RUTHERFORD: LaVon Rutherford,
- 13 no conflict, NIOSH.
- 14 MR. SHARFI: Mutty Sharfi, ORAU
- 15 team, no conflict.
- 16 MS. HARRISON-MAPLES: Monica
- 17 Harrison-Maples, ORAU team, no conflict.
- 18 MR. KATZ: I'm sorry. Two of you
- 19 trampled each other. I heard Monica Maples,
- 20 but I didn't hear the other.
- 21 MR. DAVIS: Jason Davis, ORAU
- team, no conflict.

- 1 MR. KATZ: Thank you. Very good.
- 2 And SC&A team?
- DR. MAURO: John Mauro, SC&A, no
- 4 conflict.
- DR. OSTROW: Steve Ostrow, no
- 6 conflict.
- 7 DR. ANIGSTEIN: Bob Anigstein,
- 8 SC&A, no conflict.
- 9 MR. KATZ: Thank you. Very good.
- 10 Federal officials, HHS or other agencies, or
- 11 contractors to the feds?
- MS. LIN: This is Jenny Lin, HHS.
- MS. HOWELL: Emily Howell, HHS.
- DR. AL-NABULSI: Isaf Al-Nabulsi,
- DOE.
- 16 MR. KOTSCH: Jeff Kotsch,
- 17 Department of Labor.
- 18 MR. KATZ: Very good. Thank you
- 19 and welcome. And last but not least,
- 20 petitioners or members of the public?
- 21 MS. BONSIGNORE: Antoinette
- 22 Bonsignore, Linde SEC petitioner.

1	MS. LUX: Linda Lux, petitioner.
2	MR. KATZ: Very good. Have I
3	missed anyone?
4	(No response.)
5	Okay. Thank you and welcome all.
6	Let me remind everyone on the line
7	to mute your phone except when you're
8	addressing the group. You can press *6 if you
9	don't have a mute button, and *6 to come off
LO	of mute. And please don't put the call or
L1	hold at any point, but hang up and dial back
L2	in if you need to leave.
L3	We have an agenda which was posted
L4	just this morning but distributed to the Work
L5	Group Members again on Friday, I believe. So,
L6	Gen, it's your agenda.
L7	CHAIR ROESSLER: Okay. Thank you,
L8	Ted.
L9	This is Gen. A reminder to
20	participants and I'm pleased that all of
21	the key participants are on the phone we
22	are discussing SEC-00107, Linde Ceramics.

1	This covers the period January 1, 1954,
2	through July 31, 2006.
3	This has been called the Linde
4	residual radiation period. Sometimes it is
5	also referred to as the renovation or
6	remediation period. At least a part of it
7	covers that time period.
8	I will remind you, in case you
9	want to refer to a timeline, there is one in
LO	the new Evaluation Report on page 17. I found
11	that quite helpful, and it's something that,
L2	as we go through this and as we go through the
13	Board presentation, we might want to have it
L4	in front of us.
15	I would also like to ask the Work
L6	Group that we should focus on this petition.
L7	And on and I think sometimes we, too, need
L8	to remind ourselves of the rule that we are
L9	obligated to follow, and sometimes we might

need to -- I found it rather refreshing myself

to go back this weekend and review some things

in it.

20

21

1	So our goal for the meeting today
2	is to evaluate the new materials and
3	information, and then to plan our presentation
4	for the face-to-face Board meeting on February
5	24th.
6	The agenda I think everybody on
7	the Work Group has this. I was proud I got on
8	the CDC computer on Friday and was able to
9	send it to Ted, and then it seemed that CDC's
10	email crashed. But I did send it to the Work
11	Group Members, and I think Ted said it was
12	posted this morning.
13	So the first thing, do the Work
14	Group Members or others have any additions or
15	changes to the agenda?
16	(No response.)
17	Either everybody is on mute or
18	there are none, so we'll proceed. I thought
19	it would help to do a very brief summary of
20	the December 7th of our Work Group
21	teleconference, and then the a summary of
22	the pertinent portion of the January 12th

Т	Board meeting. And the transcript, by the
2	way, for the our teleconference is on the
3	website.
4	The main issue on December 7th
5	that the Work Group discussed was how to bound
6	radon doses in the Linde conveyor tunnel.
7	NIOSH presented an approach to use radon
8	concentrations in basements. A rather
9	extensive database was found. This is in an
10	area near the site. We discussed this in-
11	depth.
12	I think SC&A agreed with the
13	approach and agreed that this would be a
14	plausible bounding method. Therefore NIOSH
15	was instructed to revise this methodology in
16	their revised Evaluation Report.
17	Then even though that was the main
18	issue that we had to discuss, we also even
19	though the bounding doses in the Linde
20	buildings had been discussed at earlier
21	meetings, and NIOSH and SC&A had agreed on
22	this bounding approach, our Work Group Members

Mike Gibson and Josie Beach said they were still concerned about the approach. We discussed some of this, and in

We discussed some of this, and in my review of our transcript and minutes and in some of the comments I made, my conclusion was that many of Mike Gibson's concerns were overarching concerns. And this -- we will give him and Josie time when we present our views to the Board in Augusta on the Linde petition -- time to express those concerns.

So then on January 12th at our Board meeting -- and this transcript is also on the website -- the pages 15 through 38, if you want to look those over, deal with Linde. At that time, NIOSH reported that they had withdrawn earlier approaches to bounding radon doses in the Linde tunnels, and they are going to be using what I described before, the basement radon measurements, and some factors based the radium adjustment on measured in soil from the site to come up with their method.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	They also agreed to modify the
2	method of external excuse me, internal
3	exposure in the building during this
4	renovation period.
5	So during this then the Board
6	meeting, because of these revisions, we
7	decided then to delay any action until after
8	NIOSH had a revised Evaluation Report, after
9	SC&A had a chance to review it, and after our
10	Work Group could schedule a meeting and
11	this is it, today so that we could decide
12	what to present at the next Board meeting in
13	February.
14	So we do have the revised
15	Evaluation Report. I'll comment that, Chris,
16	you and your team I thought put together a
17	very concise and readable document.
18	So I think the next thing on the
19	agenda, then, unless anybody has any questions
20	about or comments about what I have just
21	said, is to ask NIOSH to present their report.
22	And then I haven't seen a written response to

1	it from SC&A, but I hear Steve on the line and
2	Bob Anigstein. So I assume they will follow
3	with their comments. And I'm done talking.
4	MR. CRAWFORD: Gen, to what extent
5	do you want me to go over the modified ER?
6	This is Chris Crawford.
7	CHAIR ROESSLER: Well, I certainly
8	don't think we want to go over the whole
9	thing, but I think and everybody has had it
10	and has been reminded to read it. I think
11	just hit the high points on your revised
12	approach to bounding the radon doses, and, you
13	know, I think just summarize that as a start.
14	MR. CRAWFORD: All right. I do
15	need to point out that actually it was SC&A
16	and Bob Anigstein that came up with the basic
17	radon model that we are now using. All we did
18	was take Bob's model and we added data to the
19	data set. That is, bore holes that were near
20	the tunnels that we did use and that Bob
21	actually used, some of the data hadn't been
22	included on the original run

WASHINGTON, D.C. 20005-3701

1	Also there was a minor correction
2	to be made because Bob had inadvertently used
3	the Niagara County instead of the Erie County
4	basement radon levels. With those two things
5	added, we ran Bob's model and came up with
6	it's a little overly precise, but 99.31
7	picocuries per liter as a bounding level of
8	radon in the tunnel from the soil.
9	So if there's any discussion about
10	that, we could do that now, Gen.
11	CHAIR ROESSLER: Well, if you
12	MR. CRAWFORD: We also go
13	ahead.
14	CHAIR ROESSLER: The thing we
15	might do as you go through this is have SC&A
16	interact or comment as you present
17	information.
18	DR. OSTROW: Gen, this is Steve
19	Ostrow. I don't think that's really
20	necessary. We reviewed the new ER and the
21	other two documents that came along with it,
22	and we can just make a comment at the very end

1	of	his	presentation,	I	think.
---	----	-----	---------------	---	--------

- 2 CHAIR ROESSLER: Okay. That
- 3 sounds good.
- 4 MR. CRAWFORD: Other than that,
- 5 Gen, I think the main change to the ER was we
- 6 did go back and we did get all of the
- 7 individual Linde tunnel drawings that we had
- 8 discussed, but didn't have the actual drawings
- 9 in the last teleconference.
- 10 And we believe that they show
- 11 unequivocally that certain sections of the
- 12 tunnels were constructed at different times.
- 13 I think that's well laid out in the revised
- 14 ER. I could go over it, if you like.
- 15 CHAIR ROESSLER: No, I don't think
- 16 that would be necessary unless someone has
- 17 questions.
- 18 MR. CRAWFORD: One thing we -- we
- 19 haven't mentioned, we did get an email from
- 20 Dr. Melius.
- DR. NETON: Yes, I was just going
- 22 to suggest that we talk about the other --

1	this is Jim Neton, by the way. The other
2	modification that was made to the ER was to
3	I think we had vacuuming operations in there
4	originally, and we revised it to include this
5	pneumatic hammering value, which we had come
6	to that conclusion during our deliberations in
7	previous Working Groups. That is this 2.3 MAC
8	value that we would apply the continuous value
9	throughout the so-called renovation period.
10	And the reason for that was it
11	seemed to us to be a better indication of what
12	might be in the renovation period because it
13	was jackhammering of previously clean
14	concrete. They went back and after it had
15	already been sandblasted, I believe, they went
16	back and re-jackhammered it and ended up with
17	this 2.3 MAC, which I believe was the highest
18	value measure of the jackhammering operations.
19	And since there were worker
20	statements to the fact that jackhammering was
21	an operation that did occur during the D&D
22	or the renovation period, we felt that that

1	was a fairly representative value that we
2	would use for that reconstructions during
3	that time.
4	I think that's the gist of all
5	that has changed in the ER.
6	CHAIR ROESSLER: This is Gen. A
7	timeline on this I think Dr. Melius's
8	concerns about the lack of information on the
9	site, which I have on the agenda, but we
LO	later, but we can bring it in any time, I
L1	think I think he sent that before he saw
L2	the new ER. Is that true?
L3	DR. NETON: You know, I'm not
L4	clear on that although Dr. Melius's email had
L5	some items that I didn't quite understand.
L6	For example, he referred to a reduction in a
L7	factor of two to account for the cleanup.
L8	That was actually that's what
L9	was used in the previous ER that it was
20	involved vacuum cleaning, and we originally
21	had reduced that by a factor of two to
22	accommodate the fact that it had been cleaned

1 That's no longer in the ER, so I was a little
2 bit confused by Dr. Melius's email as to what
3 he had read to come to his conclusions.
4 CHAIR ROESSLER: This is Gen. I'm
5 wondering how we should approach this. We do
6 need to talk about Dr. Melius's comments and
7 how we are going to address them, but I'm
8 wondering if we should finish the revised EF
9 first and have comments from SC&A. What you
10 have just said, Jim, may apply to Dr. Melius's
11 concerns, but let's separate it out. Let's
finish this discussion and then go on a little
13 bit later with Dr. Melius's concerns.
So I think if that completes your
15 summary, then we should go to Steve and Bob
and SC&A's response.
DR. OSTROW: Okay. Gen, this is
18 Steve. Not much to say. We reviewed NIOSH's
19 Revision 1 of their ER, and we reviewed the
other documents that they sent us around the
21 same time. And we support their approach. We
have no comments other than that we support

1	their	approach.
_	011011	orber cororr.

- 2 CHAIR ROESSLER: So that includes
- 3 the entire approach for bounding for the
- 4 buildings and the conveyor tunnel.
- 5 DR. OSTROW: Yes, the utility
- 6 tunnel.
- 7 CHAIR ROESSLER: I mean the --
- 8 excuse me, I did that once before already,
- 9 too.
- DR. OSTROW: Okay.
- 11 CHAIR ROESSLER: Thank you, Steve.
- DR. OSTROW: Yes, the whole
- business -- we agree with your --
- 14 CHAIR ROESSLER: Okay. Okay.
- DR. OSTROW: John or Bob, do you
- have any comments on that? I think that's our
- 17 conclusion, right?
- 18 DR. ANIGSTEIN: That's our
- 19 conclusion. This is Bob Anigstein. There was
- 20 a -- there are some small differences. The
- 21 most important difference is that the -- our
- 22 original analysis used the bore hole -- the

1	radium assays from bore holes that NIOSH had
2	identified were in the vicinity of the tunnel.
3	We didn't do any you know, didn't check
4	any others. We only selected the ones that
5	NIOSH said were in the vicinity of the tunnel.
6	Now NIOSH said they used they
7	used all of the bore holes, and the result was
8	somewhat lower, about a factor of two lower
9	radium readings on average. But we decided
10	this is sort of within the realm of analyst
11	within the area of analyst judgment. So we
12	are we are willing to go along with that.
13	CHAIR ROESSLER: Okay. Work Group
14	Members, do you have any comments or concerns?
15	MEMBER FIELD: Jim, this
16	MEMBER BEACH: Oh, go ahead, Mike.
17	MEMBER FIELD: This is Bill Field.
18	Jim, I just had some questions about, you
19	know, the choice of what samples. It does
20	make a difference of about 100 picocuries per
21	liter, it looks like, depending on which ones
22	you use. Could you give us any insights into

1	why you used the ones you chose versus the
2	ones SC&A first used?
3	DR. NETON: Yes, this is Jim.
4	Chris, I think, can answer that question.
5	MR. CRAWFORD: Chris Crawford.
6	Dr. Field, actually, Bob Anigstein and SC&A
7	used all of the data that I originally sent
8	them. So it wasn't that they chose the data.
9	The only change that we made was
10	using the same bore holes, the same set of
11	bore holes, we had data down to 11 feet in
12	some cases. Originally, we only sent the data
13	for the top four feet of soil. We decided
14	later, since it was a biased sample to begin
15	with, that we might as well use the full
16	column bore hole readings. That was all that
17	was added to the data that we had.
18	MEMBER FIELD: And can you refresh
19	my memory, how deep are the tunnels again?
20	MR. CRAWFORD: The tunnels are 10
21	to 12 feet deep for the most part.

MEMBER FIELD: Okay. Okay. Thank

1	you

- MR. CRAWFORD: You're welcome.
- 3 CHAIR ROESSLER: Okay. Bill, this
- 4 is Gen. Does that -- do you have any
- 5 concerns, after hearing that, with the
- 6 approach, then, that NIOSH proposes to use?
- 7 MEMBER FIELD: No, I think it's
- 8 reasonable with the bounding they performed.
- 9 I think it's very reasonable.
- 10 CHAIR ROESSLER: Okay. Then I
- 11 think Josie had a question.
- 12 MEMBER BEACH: Yes. I just had --
- 13 back on the utility tunnels. We had
- 14 discussions at our last Work Group meeting
- 15 about the drawings and clarification of the
- drawings of when the tunnels were built, and I
- 17 know Antoinette had some issues. And I have
- 18 some concerns with those drawings, and I know
- 19 that Jim had talked about possibly getting
- 20 permits.
- 21 And I quess I still have some
- 22 concerns about when those tunnels were

1	constructed, and it looks like they have come
2	to the conclusion that they had earlier stated
3	on the tunnels, that some of them were built
4	early and some of them came later. So I'm
5	still concerned about that.
6	MR. CRAWFORD: Gen, this is Chris
7	Crawford. Do you want me to address that?
8	CHAIR ROESSLER: Yes, I wish you
9	would.
10	MR. CRAWFORD: Well, I did post in
11	the Board's area the tunnel drawings, so I'm
12	going to refer to the drawings, but you can
13	pull them up yourselves and expand the
14	drawings and see the text, to the extent you
15	wish.
16	And I would direct the your
17	attention to the 1957 Linde tunnel drawing.
18	For the record, it's the drawing number is
19	A-360164. And there are two quite significant
20	features I would like to draw to your
21	attention.

In the central lower part of the

1	drawing, there are some dashed lines. They
2	are very faint in the whole drawing, but if
3	you blow it up it's quite easy to see. And
4	they are labeled Future Extension of Tunnel,
5	and that future extension of tunnel is the
6	western extension of the tunnel from Junction
7	Box 1. That's an indication that that tunnel
8	did not exist in 1957 at the time this drawing
9	was made.
10	Also the other thing that I want
11	to direct your attention to is that there are
12	many features labeled on the drawing, but
13	conspicuously absent is Junction Box Number 6
14	in any tunnel going to the south towards
15	Building 8, which is these are construction
16	drawings, after all, and they showed old
17	abandoned sewer lines, and everything that was
18	there was shown, believe me.
19	But that's missing, and no tunnel
20	shown to the south. I think it's very good
21	evidence that those tunnels did not exist in
22	'57. Furthermore, in the 1961 drawings, we

1	see that those tunnels are drawn in. We
2	believe they were built in 1961, and I invite
3	you to look at the 1961 drawing as well for
4	that reason.
5	MEMBER BEACH: Yes. No, I
6	appreciate that. I have looked at them, and
7	the central the dotted lines you explained,
8	I'll look for that. Thank you.
9	CHAIR ROESSLER: Okay. Any other
LO	questions or comments from Work Group Members?
11	DR. NETON: Hey, Gen, this is Jim.
L2	I'd just like to point out that the existence
L3	of the tunnels really isn't necessarily
L4	relevant to our current discussion. It's more
L5	relevant to the other SEC-154 Class.
L6	MEMBER BEACH: Jim, this is Josie.
L7	I do understand that, but it was mentioned,
L8	so I thought I'd go ahead and bring it up
L9	because I did have a question.
20	DR. NETON: Yes.
21	MEMBER BEACH: Thanks.

DR. NETON: No problem.

1	CHAIR ROESSLER: This is Gen.
2	That's pertinent when we get to the Board
3	meeting, too, is if the question comes up, I
4	think we need to keep pointing out that it's
5	it really isn't a question for the SEC
6	under discussion.
7	Okay. Any other comments?
8	(No response.)
9	There probably will be some from a
10	number of you once we talk about Dr. Melius's
11	email, and which everyone has. Are we
12	ready to move on to that discussion?
13	MEMBER FIELD: I think so.
14	CHAIR ROESSLER: And then after we
15	finish that, then we will try to wrap up what
16	the Work Group Members think we should do with
17	regard to our presentation to the Board.
18	I did forward to you I believe
19	I did, to the Work Group Members, and I think
20	you all were copied on it originally when Dr.
21	Melius sent out his email his concerns
22	and I've highlighted on here, I'll kind of

1 outline this, and then we can just discuss 2 from that -- that he says that he is primarily 3 concerned with the part of the timeline that we call the remediation time. 4 And he says -- oh, let me see if I 5 6 can find it -- because there is lack of information on the activities at the site, he 7 is questioning the extent of the time period 8 involved, the number of workers, type of 9 renovation activities, involvement of workers 10 from other parts of the facility -- let's see, 11 I'm still not getting to the bottom line here. 12 13 What he's questioning is actually coming up with the bounding approaches for 14 15 this particular period of time. And I think Jim addressed -- Jim Neton addressed this in 16 part in the -- by discussing the new ER and 17 talking about using probably a much more 18 19 claimant-friendly approach to doing this by 20 using values from the pneumatic hammering during the earlier decontamination part of the 21

site.

1	Have I summarized that okay, or
2	does somebody else want to give a shot at it?
3	(No response.)
4	It doesn't sound like it.
5	MEMBER LOCKEY: Gen, Jim Lockey.
6	Can you hear me?
7	CHAIR ROESSLER: Sure.
8	MEMBER LOCKEY: Okay. When I read
9	Jim's letter, I was more struck with not
10	struck, but thinking he was saying that we
11	couldn't do dose reconstruction with
12	sufficient accuracy because there wasn't
13	enough sampling available. And even though we
14	were taking a claimant-friendly approach, dose
15	reconstruction was not going to be an accurate
16	dose reconstruction.
17	Now I really don't know how to
18	address that. The only way you really get
19	accurate dose reconstruction on each worker is
20	to have each worker monitored on a continuous
21	basis, and that's the only way you'll get
22	accurate data on any workplace situation.

1	So I'm not sure how to address
2	that, but I thought that was the question he
3	was asking.
4	CHAIR ROESSLER: Well, let's see.
5	Jim Neton or Chris Crawford, what is your
6	interpretation of his concern?
7	DR. NETON: This is Jim Neton. I
8	would agree with Dr. Lockey's assessment of
9	Dr. Melius's concern, that it wasn't that we
10	couldn't we didn't have some sort of a
11	bound that we could put there, but it was is
12	that a reasonable bound to use for all workers
13	in all buildings, that sort of thing.
14	And that's I'm not sure how one
15	addresses that. This is not unlike what we do
16	when we use 95th percentiles for all workers
17	at certain sites or, you know, any time we
18	can't position a worker at a time and place,
19	we very often resort to upper bounds, full
20	well knowing that not all workers actually
21	participated in all of those activities. But
22	it's claimant favorable. So I'm not exactly

1	sure where to go with that.
2	MR. CRAWFORD: And I would sort of
3	agree with that. That question sort of throws
4	into question even using a 95th percentile as
5	an upper bound because it probably does not
6	reflect accurately what dose a person got. It
7	probably overestimates the dose by a factor of
8	10 to 100. Therefore that would not be
9	considered an accurate dose reconstruction for
LO	that individual.
L1	The only way I know that can be
L2	resolved is in these situations, if you want
L3	that degree of accuracy, every person has to
L4	have personal monitoring data.
L5	CHAIR ROESSLER: This is Gen.
L6	Would it be fair to say that he is saying that
L7	this is not a plausible upper bound for
L8	everyone at the site?
L9	MR. CRAWFORD: I don't think he's
20	saying that. I think what he is saying is
21	that it's not accurate, and that there are
22	probably people substantially lower

1	CHAIR ROESSLER: And so it seems
2	like this has been done at other sites. It
3	would be like I call it often an
4	overarching problem. If this is a problem at
5	this site, then certainly it would be at other
6	sites other sites that have even been
7	the decision has been made.
8	MR. CRAWFORD: It would be a
9	universal problem across the whole industry.
10	MEMBER FIELD: Gen, this is Bill
11	Field. I read his questions, I guess, a lot
12	differently. I don't think he has seen this
13	one with the new assumptions. I think what
14	from my perspective what he was asking is
15	could they have been involved in some type of
16	activities where they would have had higher
17	exposure than what the assumptions were that
18	were being used? That was my interpretation.
19	CHAIR ROESSLER: That was what
20	that was the way I interpreted it, too. And
21	that's why I thought perhaps the revision to
22	the ER to include the pneumatic hammering

1	might take care of that. I don't know that
2	MEMBER LOCKEY: Gen, I would refer
3	you and Bill to the bottom of his I don't
4	know, the second paragraph or third paragraph,
5	the one that starts, "Given the paucity of
6	information and data," the very last sentence
7	in his email, "Simply being able to apply
8	worst-case exposure scenarios to everyone at
9	the site during this time period may satisfy
10	our policy for being claimant-friendly, but it
11	does not necessarily justify the need to be
12	able to do dose reconstruction with sufficient
13	accuracy."
14	CHAIR ROESSLER: Yes. So that
15	that then supports your conclusion as to what
16	his concerns were.
17	MEMBER LOCKEY: Yes.
18	CHAIR ROESSLER: I'm wondering,
19	have we actually gotten two communications
20	from him? I have another one, and I'm looking
21	at that now to see if that's if that's
22	different. This was one that he sent out on

1	January 10th, and here he says, "I have two
2	questions on Linde."
3	MEMBER BEACH: That's the original
4	one, Gen. This is Josie.
5	CHAIR ROESSLER: Yes. And so how
6	
7	MEMBER BEACH: There is two.
8	CHAIR ROESSLER: And I'm looking
9	at that quickly here. Without he says,
LO	"Without knowledge of the renovation
L1	activities, could you be underestimating
L2	exposures for the Building 30 workers and at
L3	the same time overestimating the exposures for
L4	workers in other buildings?" He says, "While
L5	we can argue you are bounding the dose, that
L6	bound must be plausible."
L7	I'm not really clear on what his
L8	concerns are, and I'm not quite sure how we
L9	should handle it.
20	MR. KATZ: Gen, this is Ted. I
21	would just suggest you be prepared to handle

either side of the question.

1	CHAIR ROESSLER: Okay. There
2	was
3	MR. KATZ: That seems like the
4	easiest way.
5	CHAIR ROESSLER: Yes, I know.
6	There was some communication on email that I
7	saw between Dr. Melius and SC&A, and there was
8	some talk about a technical call. Did that
9	ever happen, or does anybody from SC&A have
10	any clarification on that?
11	DR. OSTROW: No, we didn't have
12	any technical call because it's not really the
13	right venue. Technical calls are usually
14	between SC&A and NIOSH and involve some
15	technical issue where we don't understand what
16	they're doing, and they don't understand what
17	we're doing, so it's a clarification.
18	We don't I don't think we have
19	technical calls with Board Members, in
20	general. So we didn't have such a thing. And
21	I don't know if it's really the place of SC&A
22	to answer this.

1	MEMBER LOCKEY: Hey, Gen, Jim
2	Lockey. Let's go through his email because
3	there is a couple of things I would like to
4	know. I think he raises some questions that I
5	need to be clarified on. Maybe, Steve, you
6	could do it for me.
7	But in relationship to the Linde
8	site, when we are talking about Building 30,
9	how many other buildings besides Building 30
10	are we talking about in relationship to this
11	SEC?
12	CHAIR ROESSLER: Chris could
13	probably answer that.
14	DR. NETON: Chris Crawford. Yes,
15	I'm sorry.
16	MR. CRAWFORD: Basically, we are
17	talking about the four buildings in the
18	ceramics plant area, plus Building 14 also
19	called the Tonawanda Laboratory, among other
20	things.
21	MEMBER LOCKEY: And Building 30
22	was chosen because?

1	MR. CRAWFORD: It was the most
2	heavily contaminated of all the ceramics plant
3	buildings, and it was where the primary
4	uranium ore processing was done, which
5	explains the contamination level.
6	MEMBER LOCKEY: And we have good
7	documentation that it was the heaviest
8	contaminated building?
9	MR. CRAWFORD: Yes. It is stated
10	in several reports, both contemporaneous
11	reports back in the '50s and also in the
12	FUSRAP reports later.
13	MEMBER BEACH: If you look on the
14	ER on page 14, it lists all of the buildings
15	out
16	MEMBER LOCKEY: Right. I know
17	that. I'm just trying to run through what Jim
18	was running through in my mind.
19	In relationship, then, to
20	Building 30, we can't document which workers
21	went in and out of which buildings, is that
22	correct?

1	MR. CRAWFORD: That's basically
2	correct. Apparently, workers traveled quite a
3	bit through the plant. And, of course, we are
4	dealing with a 50-year period here. Workers
5	are reassigned regularly, too, so no, we can't
6	place individual workers and individual
7	positions within buildings.
8	DR. NETON: This is not unlike we
9	have done at almost every other site.
10	MEMBER LOCKEY: It would be sort
11	of like General Electric, right?
12	DR. NETON: Exactly.
13	MEMBER LOCKEY: Exactly. Okay.
14	So when we get to, then, the question about
15	renovation activities in Building 30, there is
16	very little documentation of those activities.
17	And when I read the documents, there wasn't a
18	lot of there wasn't a lot of paperwork
19	documentation that a lot of renovation went
20	on, but I guess the workers thought that a lot
21	of renovation went on. Is that correct? Am I
22	reading that right?

1	MR. CRAWFORD: That is correct.
2	In my reading of the worker testimony, there
3	is one incident that seems to stand out as
4	well described a 1966, I think, movement of
5	an industrial shears, which was, I think, a
6	six-month project. The rest is testimony that
7	basically there was a lot of work done in the
8	buildings from '62 to '68 in particular.
9	NIOSH did discover one
10	construction permit for a very small addition
11	to Building 30 that was done in 1968. We
12	don't actually know if the work was done, but
13	the permit was issued. So those are the only
14	two fact points we have a '66 movement of a
15	machine and a '68 building permit. Everything
16	else is a little vague.
17	DR. NETON: But we do know for a
18	fact that jackhammering did occur because
19	there is testimony in various proceedings to
20	that effect.
21	MEMBER LOCKEY: Okay. So then
22	when Jim raises the question of the extent of

1	the time period that workers were involved,
2	the type of renovation activities, involvement
3	of other workers from other parts of the
4	facility, then overall, I guess the approach
5	we have taken, as I understand it, is we have
6	taken the worst-case situation in Building 30,
7	the worst type of renovation that probably can
8	happen that was the jackhammering and the
9	generation of dust and assuming that all of
10	the workers from all of the facilities had the
11	potential for that exposure over that period
12	of time.
13	DR. NETON: That's correct.
14	MEMBER LOCKEY: Okay. So then his
15	real question is, is that of sufficient
16	accuracy?
17	CHAIR ROESSLER: Well, I think his
18	question is would the exposures be
19	underestimated in Building 30? I think that's
20	really the pertinent question. His question
21	about overestimating in the other buildings,
22	you know, that's a precedent. That is done

1	sort of routinely, and I don't think that
2	would be to me, that's not the major
3	question to address.
4	MEMBER LOCKEY: Right, Gen. You
5	know, for me it's confusing. I'm not sure
6	I thought he was concerned about sufficient
7	accuracy. Even though we're being claimant-
8	friendly, we may it's not an accurate
9	reconstruction because it may be too high.
10	But you're right, he may be
11	thinking that we don't have enough data to
12	claim that we are upper bounding it. But it
13	sounds like SC&A and NIOSH thinks we do have
14	enough data.
15	MEMBER FIELD: This is Bill Field.
16	It seems like if jackhammering occurred
17	and that's documented Jim or anyone else,
18	can you think of any other type of activity
19	that would have created a higher exposure?
20	DR. NETON: Not once the not
21	once the building had been cleaned. See, we
22	had some fairly detailed surveys while they

1	were while they were deconning the
2	building. And sandblasting, certainly, of
3	contaminated concrete that had not been
4	cleaned is much higher. I mean, that's a
5	fact.
6	But of the other activities that
7	remain once the material has been cleaned
8	through sandblasting and vacuuming and such,
9	the highest value that would exist would be
10	the jackhammering of the previously cleaned
11	materials, which is what we used. And I
12	believe we used the highest of those of the
13	jackhammering values. There were other
14	jackhammerings, but we took the highest one,
15	which was 2.3 times the maximum allowable
16	concentration.
17	MEMBER FIELD: And the assumption
18	was for Building 30 and others that that
19	jackhammering occurred 24 hours a day.
20	DR. NETON: Well, yes, or every
21	hour a worker was
22	MEMBER FIELD: Every hour that

1	there	was	produced	that	concentration.

- DR. NETON: Yes.
- 3 MEMBER FIELD: So if anything
- 4 seems implausible to me it's that, that you
- 5 would have those concentrations over a 24-hour
- 6 period. But, you know, I guess that gets into
- 7 the gray area of what's plausible.
- DR. NETON: Right.
- 9 MEMBER LOCKEY: This is Jim
- 10 Lockey. Bill, you're right, it's not --
- 11 that's not plausible, but it does set a
- 12 claimant-friendly upper bound on it. But the
- 13 question is is it accurate, right? And that's
- 14 why I thought that's what Jim was asking.
- DR. MAURO: This is John Mauro.
- 16 The essence of the issue really goes to OTIB-
- 17 70. In other words, there has been -- in
- 18 effect, the concern is whether or not this
- 19 fundamental strategy of using data collected
- 20 during the D&D period -- 1953 selecting that
- 21 data in a way that you feel could be applied
- 22 to the renovation period.

1	It is a classic OTIB-70 approach
2	with a little twist to it to make it even a
3	little bit more conservative because you are
4	holding it flat. And I really think what you
5	are going to is the fundamental philosophy, or
6	there may even be what you consider to be a
7	policy issue, whether that basic approach to
8	deal with residual periods in general, because
9	residual periods very often have very little
10	if no data until the FUSRAP program starts.
11	And NIOSH has come up with a
12	strategy, with the OTIB-70 strategy, and there
13	is, you know, many ways in which that could be
14	implemented. But it is a fundamental approach
15	to deal with time periods where you have very
16	little data because at the time they felt
17	there really was very little potential for
18	exposure.
19	And whether or not that approach
20	is something that satisfies and it's almost
21	your sense of sufficient accuracy within the
22	context of the regulations. And, of course,

WASHINGTON, D.C. 20005-3701

2	this meets what you feel is a threshold
3	criteria of what sufficient accuracy is.
4	I wanted to just throw that in
5	because the very issue that we're discussing
6	goes toward OTIB-70 and that fundamental
7	philosophy. And it is going to be very
8	important as it applies to many, many other
9	sites.
LO	DR. NETON: John, this is Jim. I
L1	appreciate that comment. You hit the nail on
L2	the head. And I'd point out that this is not
L3	unlike what TIB-70 does for almost every other
L4	site where we have operational air sample data
L5	during the operations, and we use that to set
L6	the intakes at the start of the residual
L7	period. It's very much akin to that with a
L8	little bit of a twist. But you're absolutely
L9	right.
20	MEMBER BEACH: This is Josie. Car
21	I ask a question here, Jim? Or I'm not sure
22	who can answer it. Has OTIB-70 been reviewed

now it's really your interpretation of whether

1

1	hv	the	Procedures	Work	Group?
上	IJУ	$c_{11}c$	Procedures	MOTV	Group:

- DR. NETON: It's under review at
- 3 the current time.
- 4 MEMBER BEACH: Okay. Because I've
- 5 been trying to find that documentation and
- 6 haven't been successful.
- 7 DR. NETON: There is an SC&A
- 8 review that has been produced, I believe.
- 9 Yes. And --
- 10 MEMBER BEACH: -- available on the
- 11 NIOSH website or --
- DR. NETON: No. It should be. If
- not, we can certainly make it available.
- Now this is the crux of the issue.
- 15 TIB-70 has been reviewed, but I will say that
- thus far during the review the starting point
- of TIB-70, this -- this sort of decay using
- 18 data from the operational period has been
- 19 favorably reviewed by SC&A.
- DR. MAURO: Yes, and I'll --
- 21 MEMBER LOCKEY: -- some other
- issues that are on the table, but that one I

1	believe is we are in general agreement on.
2	DR. MAURO: This is John Mauro.
3	That's correct. There are many facets to
4	OTIB-70, only one of which deals with the
5	subject we are talking about right now, which
6	is I would say the most important part of
7	OTIB-70. And we have concurred in that
8	particular aspect of OTIB-70 that is, this
9	the way in which it is being applied here.
10	So there is still lots of
11	discussion going on regarding OTIB-70, but
12	this particular aspect of it has been in
13	SC&A's perspective been resolved.
14	MEMBER BEACH: Correct. Okay.
15	DR. NETON: I will mention that I
16	am slotted to give a presentation on OTIB-70
17	at the upcoming Advisory Board meeting. That
18	was requested by, I believe, Dr. Melius.
19	MR. KATZ: Right. This is Ted.
20	And that's on the first day in the morning.
21	CHAIR ROESSLER: This is Gen. Our
22	Work Group report is on the second day, I

1 think.

2 MR. KATZ: That's correct. So

3 everyone will have the advantage of that

4 discussion before you get to the discussion

5 about Linde.

6 CHAIR ROESSLER: This is Gen. The

7 other thing it seems that we need to do is to

8 -- and if this is permissible -- is for me or

9 someone to contact Dr. Melius and see if we

10 can ask him to be much more specific, and I

11 can ask him some questions and give some of

our discussion from today, ask him to be much

13 more specific about his concerns because I

think we really -- it seems to be the crux of

15 the whole situation, and we really need to

16 clarify it at the Board meeting. If we can't

17 clarify it, I hate to see that we would delay

18 any further on this.

19 MEMBER LOCKEY: And, Gen, I agree

20 with that. I think we have to make it -- the

21 decision for the benefit of the workers rather

in carrying this forward again.

1	Chris? This is Jim Lockey.
2	MR. CRAWFORD: Yes.
3	MEMBER LOCKEY: Chris Crawford,
4	let me ask you a question about the
5	sandblasting that was done. Was that how
6	complete was that?
7	MR. CRAWFORD: Complete in the
8	the decon period?
9	MEMBER LOCKEY: Right.
LO	MR. CRAWFORD: Well, they did a
L1	building survey. I think they took like 7,000
L2	readings in Buildings 30 and 31 at least. And
L3	where there was areas of high contamination,
L4	they used several methods, including
L5	sandblasting, chipping, jackhammering, I
L6	believe they used blowtorches
L7	DR. NETON: And they also cemented
L8	over areas that couldn't be cleaned.
L9	MR. CRAWFORD: Right. They
20	washed, they vacuumed, they painted and
21	cemented over, they removed wood and concrete.
22	DR. NETON: But that's not to say

	1	that	it	was	perfectly	clean.
--	---	------	----	-----	-----------	--------

- 2 MR. CRAWFORD: Right. But we do
- 3 have quite a good record of the before and
- 4 after readings, which indicates that a lot of
- 5 material was in fact removed. And what was
- 6 left was mostly fixed contamination at fairly
- 7 low level.
- 8 MEMBER LOCKEY: Chris, could it be
- 9 possible that you could present that data also
- 10 at the next Board meeting?
- 11 MR. CRAWFORD: Yes, during the
- 12 Linde discussion, I would be happy to. Also I
- 13 can put the -- I believe it's the Heatherton
- 14 document that has that information on it. I
- 15 can put that in the Board's area, and I'll
- send out a note to everyone.
- 17 MEMBER LOCKEY: That would be
- 18 helpful. I'd like to look at that again.
- 19 MR. CRAWFORD: It may already be
- 20 there, Bomber tells me. But if so, I'll give
- 21 you a pointer to it.
- 22 MEMBER LOCKEY: Perfect.

1	CHAIR ROESSLER: Since the last
2	Board meeting, it seems that the presentation
3	should revolve around the bounding doses in
4	the tunnels using this new approach. And
5	then, also, since the question has come up
6	about the bounding in the buildings,
7	particularly Building 30, I think that it
8	would be appropriate, Chris, for you to
9	address that as Dr. Lockey has suggested.
10	MR. CRAWFORD: I will be happy to
11	do that, Gen. You mean at the meeting, I
12	assume?
13	CHAIR ROESSLER: At the meeting.
14	I think we have to assume that the Board will
15	need a review and a summarization of the main
16	items that might be of concern.
17	MR. CRAWFORD: Again, I'll be
18	happy to do that.
19	CHAIR ROESSLER: Does anyone else
20	have any enlightenment on Dr. Melius's
21	comments or anything else that we need to
22	discuss?

Τ	(No response.)
2	Ted, are we inviting petitioners
3	to make comments at this time? Is that
4	MR. KATZ: Yes. I mean, I think
5	you should, but and then, I think you
6	probably need just to wrap up and recap what
7	it is you're going to be who is going to be
8	presenting on what at for the Work Group.
9	CHAIR ROESSLER: Right. I think
LO	that is the main main item that we have to
L1	decide is how we are going to make the
L2	presentation, who is going to present at the
13	Board meeting.
L4	So then I think it would be
L5	appropriate at this time for, Antoinette, if
L6	you wish to make some comments.
L7	MS. BONSIGNORE: I don't have any
L8	comments to make, Gen. Thank you.
L9	CHAIR ROESSLER: Okay. And Linda
20	I think is on the line.
21	MS. LUX: Yes. I don't have any
22	comments right now either. Thank you.

1	CHAIR ROESSLER: Okay. Now I
2	think what we need to talk about at this point
3	is the Work Group's evaluation of where we're
4	at. The last time we had a Work Group meeting
5	where we actually tried to take a vote we came
6	out with a Work Group of four we came out
7	two and two. Two of us said that we went
8	along with the NIOSH recommendation that they
9	could do dose reconstruction for this period
10	of time, and I think two have some concerns
11	about that.
12	Do any of the Work Group Members
13	want to make comments on where they're at on
14	their evaluation at this point?
15	(No response.)
16	Was I on mute or something?
17	(Laughter.)
18	MEMBER LOCKEY: No, this is Jim
19	Lockey. I think that the I think we can do
20	dose reconstruction during this period. I
21	think that we have answered all the questions
22	we can answer. I do need some clarification

Т	about the direction that Jim is going, and
2	that will be probably a topic for the Board
3	meeting as a whole.
4	But in relationship to this
5	particular petition, I think we can do dose
6	reconstruction in a manner that is claimant-
7	friendly.
8	CHAIR ROESSLER: Josie or Mike, do
9	you have comments?
10	MEMBER GIBSON: Well, this is
11	Mike. I'm just a little hesitant to give my
12	comments. It seems that comments made about
13	people who have experience out in the field
14	that's practical and it's outside the realm
15	of science they seem to be pigeonholed.
16	So just suffice it to say that I'm
17	not totally in agreement with using data from
18	one time period to try to evaluate what went
19	on in another time period, and that is based
20	on my pigeonholed experience that when
21	contamination areas in a renovation in a
22	decon period are just cemented over, as has

1	been discussed, and then those are
2	jackhammered up in a later time period, you
3	don't have the same you can't use the same
4	data from one period to another.
5	CHAIR ROESSLER: So if we, at the
6	Board meeting, present a motion that we feel
7	that dose reconstruction can be done for this
8	site during those time periods, would you then
9	I would assume that well, I'm not going
10	to assume. Would you vote for or against it?
11	And I guess based on that, then, we need to
12	decide how we would handle this.
13	I guess, really, I am kind of
14	getting you in the corner I think. Mike, what
15	I would like to ask is when we make this
16	presentation, would we do it similar to the
17	presentation we did the last time to the Board
18	where I try to present, Dr. Lockey and I would
19	present what we feel the conclusion is, and
20	then, if you, Mike and Josie, wish to make
21	comments with your concerns, does that seem
22	like the right approach, so that the Board has

1	everything on the table to evaluate?
2	MEMBER GIBSON: Well, actually, I
3	gave my opinions on that before the last Board
4	meeting. And no one seemed to or at least
5	some Work Group Members didn't seem to agree
6	with it.
7	But I think that Wanda did an
8	excellent job in an older previous Work Group
9	meeting when the Work Group was divided, she
10	was the Chair of the Work Group, and she got
11	up and she presented the timeline and what had
12	been discussed and that two Members agreed,
13	two Members disagreed, here's why. It saved
14	time. And then the Board had the time to just
15	have an open discussion and ask questions that
16	they thought were relevant.
17	CHAIR ROESSLER: Okay. Well, I
18	think I can do that. I would certainly,
19	first, contact Dr. Melius and get some
20	clarification on his comments. But then I
21	could present pretty much what we presented at

the last Board meeting, but update everything

22

_	1			
7	with	+ ha	70 0 547	ᄗ
	$M \perp \Gamma \Gamma \Gamma$	ric	TICM	ĽI.

- 2 I will certainly comment that SC&A
- 3 has concurred with the approaches that NIOSH
- 4 would plan to make, and then I would try to
- 5 summarize your comments, Mike, and I think
- 6 Josie's comments, if that seems appropriate.
- 7 MEMBER BEACH: Gen, this is Josie.
- 8 I think that sounds like a good approach to
- 9 me as well.
- 10 MEMBER GIBSON: This is Mike.
- 11 It's fine with me.
- 12 CHAIR ROESSLER: There's not a lot
- of time between now and the Board meeting, but
- 14 what I'd like to do is put something together
- and pass the -- put a presentation together --
- no, let me back up a bit -- try to contact Dr.
- 17 Melius, then put a presentation together, pass
- it by all Work Group Members, and then we'll
- 19 go from there.
- 20 MEMBER LOCKEY: Gen, this is Jim
- 21 Lockey. Sounds fine with me.
- 22 CHAIR ROESSLER: Okay. And we

1	will also expect NIOSH and SC&A to be on board
2	to go over a few specific things, just to
3	present the approach that they are taking, as
4	we have done in this meeting today.
5	DR. MAURO: Gen, would you be
6	looking for SC&A just to answer any questions
7	or to come up to the mic, or Steve could be on
8	the line, and Bob on the line? If there are
9	any questions for SC&A, either I if I can
10	handle it, I will, because I will be there.
11	But Bob and Steve are not planning to attend
12	the meeting, but they certainly could be on
13	the phone to answer questions.
14	The reason I ask the question is
15	if you're looking for an SC&A presentation,
16	then I would suggest that Steve physically
17	participate at the meeting and make that
18	presentation.
19	CHAIR ROESSLER: You know, John,
20	at this point, I don't think it would be
21	necessary since they could be available by
22	phone. And I think you have always stepped up

1	to	the	plate	and	have	been	able	to	summarize

- and interpret and comment on any issues. I
- 3 would think that would be fine for you to be
- 4 at the meeting and have Bob and Steve
- 5 available by phone.
- 6 DR. MAURO: Very good. No, that's
- 7 fine. I just wanted to make sure. Okay.
- 8 CHAIR ROESSLER: Okay. Is there
- 9 anything else that we need to discuss, or do
- 10 we have a plan?
- 11 MEMBER LOCKEY: It sounds like we
- 12 have a plan.
- 13 MEMBER FIELD: Gen, when you send
- 14 -- this is Bill. When you send out your --
- what you are going to present at the meeting,
- 16 you know, just make sure you give us a time
- 17 that you need it back by.
- 18 CHAIR ROESSLER: Oh, sure. Okay.
- 19 Will do. Well, let's see, this is Monday,
- 20 the -- I think our presentation is a week and
- 21 a day from now. I'll try and get something
- 22 out within a couple of days and expect a

1	response	perhaps	by	Friday.	I'm	kind	of	going
---	----------	---------	----	---------	-----	------	----	-------

- off the top of my head here. People will
- 3 probably be traveling already on Monday or
- 4 Tuesday of next week.
- 5 MEMBER FIELD: Right.
- 6 CHAIR ROESSLER: I'll try and --
- 7 I'll try and get in touch with Dr. Melius
- 8 later today or early tomorrow. I'm on travel
- 9 today, too. And then get something put
- 10 together fairly quickly. Let's say I'll try
- and get it out to you by Wednesday.
- 12 MEMBER BEACH: That sounds
- 13 reasonable, Gen. Thanks.
- 14 CHAIR ROESSLER: Okay. Anything
- 15 else that we need to cover?
- 16 (No response.)
- Okay. Ted, is there anything that
- 18 you can think of?
- 19 MR. KATZ: No, I think -- I think
- 20 you're in good shape. Gen, if you need -- if
- 21 you need Dr. Melius's phone number, I can
- 22 email it to you.

1	CHAIR ROESSLER: I didn't hear
2	that.
3	MR. KATZ: If you need Dr.
4	Melius's phone number I don't know if you
5	have it I can send it to you.
6	CHAIR ROESSLER: Oh, that would be
7	good if you could send it. And I was thinking
8	of communicating with him by email because -
9	MR. KATZ: That's fine, too.
10	CHAIR ROESSLER: Yes. I think
11	that's a little bit better. You have written
12	a written record of what you have
13	discussed.
14	MR. KATZ: Sure. Okay.
15	CHAIR ROESSLER: But send me his
16	phone number anyway, just in case.
17	MR. KATZ: Okay. I'll do that.
18	MEMBER LOCKEY: Hey, Ted, Jim
19	Lockey. Give me a call when you get done,
20	would you?
21	MR. KATZ: I will do that. Do you
22	want to email me your number or do you want

1	to tell it	to me on	the phone	?		
2		MEMBER	LOCKEY:	That	:'s	fine.
3	(513) 558-0	0030.				
4		MR. KAT	z: I'll	call	you	right
5	after this					
6		MEMBER	LOCKEY:	Okay.	Th	anks,
7	Ted.					
8		CHAIR R	OESSLER:	Okay	•	Well,
9	thank you,	Board Me	mbers and	NIOSH,	SC&A	, and
10	all others	. I thin	we're fin	nished.		
11		MR. KATZ	: Thank y	ou, eve	rybod	ly.
12		(Whereup	on, the	abov	e-ent	itled
13	matter went	off the	record at	12:01	p.m.)	
14						
15						
16						
17						
18						
19						
20						
21						

WASHINGTON, D.C. 20005-3701